ALS THERAPY DEV INST has a total of 11 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and medical technology are UNIV NIJMEGEN, NOVAGEN HOLDING CORP and NEURONAX.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Canada | 1 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | Japan | 1 | |
#6 | Republic of Korea | 1 | |
#7 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Medical technology | |
#4 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Acyclic or carbocyclic compounds | |
#5 | Diagnosis and surgery |
# | Name | Total Patents |
---|---|---|
#1 | Gill Alan | 10 |
#2 | Perrin Steven | 6 |
#3 | Vieira Fernando | 5 |
#4 | Perrin Steven N | 4 |
#5 | Gill Cynthia A | 4 |
#6 | Jiang Bingbing | 4 |
#7 | Lincecum John M | 3 |
#8 | Lincecum John | 3 |
#9 | Vieira Fernando G | 3 |
#10 | Lincecum John C | 1 |
Publication | Filing date | Title |
---|---|---|
US2017231558A1 | Measurement Of ALS Progression Based On Kinetic Data | |
US2013295092A1 | Method for the treatment of neurodegenerative diseases | |
US2013150454A1 | Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis | |
EP2367849A1 | Method for the treatment of neurodegenerative diseases |